FDA Clears Way for Clinical Trial of VOR33 Stem Cell Therapy

FDA Clears Way for Clinical Trial of VOR33 Stem Cell Therapy

284580

FDA Clears Way for Clinical Trial of VOR33 Stem Cell Therapy

Vor Biopharma has been cleared in the U.S. to begin clinical trial testing of its investigational cell therapy, VOR33, for acute myeloid leukemia (AML). The U.S. Food and Drug Administration (FDA) cleared the company’s investigational new drug (IND) application, which will enable the start of a Phase 1/2a trial in the first half of this year. “Clearance of this IND is the culmination of an incredible team effort at Vor and represents a key milestone…

You must be logged in to read/download the full post.